This Phase 2 study is looking at how well a procedure called Sentinel Lymph Node Biopsy (SLNB) works for people with a high-risk type of skin cancer on the head and neck, called cutaneous squamous cell carcinoma (cSCC). This cancer has not spread to the lymph nodes yet (clinically node-negative, or cN0). The study will involve removing sentinel lymph nodes (the first lymph nodes where cancer cells might spread) and potentially other lymph nodes (lymphadenectomy), followed by standard cancer treatments like radiation or chemotherapy (Adjuvant Definitive Therapy). The main goal is to see how many people remain disease-free two years after their treatment. You may be able to join if you are 18 or older and have high-risk cSCC of the head and neck, such as cancer in the ear or lip, or if it's larger than 2 cm. The current recruitment status is unclear.

Study design

This is a Phase 2 study at a single location, involving 24 participants. It is a pragmatic study, meaning it aims to test the intervention in real-world conditions.

What's involved

You would undergo preoperative imaging (lymphoscintigraphy), surgery to remove sentinel lymph nodes and potentially other lymph nodes, and then receive standard cancer treatments. You will be monitored for side effects during and after the SLNB procedure.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to two years after completing their definitive therapy to measure disease-free survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.